Breaking News

AbbVie Opts to Acquire Mitokinin

Following completion of IND enabling studies on Mitokinin's lead PINK1 compound for Parkinson's disease.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie has purchased an exclusive right to acquire Mitokinin, a biotech company developing PINK1-targeted therapeutics for neurodegenerative diseases, following completion of IND enabling studies on Mitokinin’s lead PINK1 compound.   Mitokinin’s novel PINK1 compounds selectively increase the activity of PINK1, a master regulator of mitochondrial quality control that is genetically linked to Parkinson’s disease.  By increasing PINK1 activity, Mitokinin aims to address the mit...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters